オプションチェーンは、Enovixの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Enovixの市場センチメントを評価します。.

Enovix (NASDAQ:ENVX) 株価情報, オプションチェーン

ENOVIX CORP

Enovix

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.

Mid Cap

News

Movers

CRDO

DJTWW

ENVX

FIZZ

GLBE

GRND

KVYO

STAA

TGLS

先週、これらの中型株は最も優れた業績を発揮しました。あなたのポートフォリオには含まれていますか？

中小株式市場　今週注目の10銘柄

Enovix Corp

UBS analyst Mark Carden maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Neutral and lowers the price target from $23 to $20.

Price Target

Analyst Ratings

WRBY

UBS Maintains Neutral on Warby Parker, Lowers Price Target to $20

UBS analyst Michael Goldsmith maintains Essential Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) with a Buy and lowers the price target from $40 to $37.

EPRT

UBS Maintains Buy on Essential Properties, Lowers Price Target to $37

iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) reported topline results from an updated interim analysis of the GALAXIES Lung-201 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45372515/iteos-reports-topline-interim-results-from-galaxies-lung-201-study-of-belrestotug-dostarlimab-in-f" rel="noreferrer noopener">Phase 2 study on Tuesday</a>.
The trial sponsored by GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) assessed the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced, or metastatic PD-L1 high non-small <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
The GALAXIES Lung-201 data demonstrated clinically meaningful improvements in the trial&#8217;s objective response rate (ORR) endpoint.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45100064" rel="noreferrer noopener">Britain&#8217;s GSK Asserts It Is &#8216;Well Positioned&#8217; To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales</a>
However, the analysis did not meet established criteria for clinically meaningful improvements in the secondary endpoint of progression-free survival in the belrestotug + dostarlimab combination cohorts versus dostarlimab monotherapy.
An interim analysis of the GALAXIES H&amp;N-202 Phase 2 trial showed a trend below the meaningful threshold for ORR in the belrestotug combination cohorts vs. dostarlimab monotherapy in PD-L1 positive head and neck squamous cell carcinoma.
Based on these results, iTeos and GSK have decided to terminate the belrestotug development program and end the collaboration. All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial will end.
iTeos Therapeutics said it is taking immediate steps to preserve capital and has initiated a targeted process to identify opportunities that preserve and maximize shareholder value. iTeos has engaged TD Cowen to advise on this process. 
&#8220;Given current market conditions and our appreciation of the responsibility to our valued shareholders, we believe the best path forward is to promptly evaluate a full range of strategic alternatives to unlock the value of our assets. With a strong balance sheet and a commitment to disciplined execution, we are well-positioned to pursue opportunities that maximize shareholder value,&#8221;&nbsp;said Michel Detheux, president and CEO of iTeos.
In April, iTeos said its cash and investments position was $624.3 million as of March 31, 2025, which is expected to provide a cash <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45053301/iteos-reports-first-quarter-2025-financial-results-and-provides-business-updates" rel="noreferrer noopener">runway into 2027</a>.
Price Action: ITOS stock is up 17.3% at $8.12 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45376829/cyberark-stock-slips-despite-strong-q1-growth-in-subscriptions-and-raised-2025-outlook" target="_blank" rel="noreferrer noopener">CyberArk Stock Slips Despite Strong Q1 Growth In Subscriptions And Raised 2025 Outlook</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Health Care

General

ITOS

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile

<a href="https://www.bloomberg.com/news/articles/2025-05-13/openai-weighs-uae-data-center-deal-as-trump-set-to-visit?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-13/openai-weighs-uae-data-center-deal-as-trump-set-to-visit?embedded-checkout=true</a>

MSFT

'OpenAI Weighs UAE Data Center Deal as Trump Set to Visit'- Bloomberg

UBS analyst A.J. Rice maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Neutral and lowers the price target from $18.61 to $16.5.

CCRN

UBS Maintains Neutral on Cross Country Healthcare, Lowers Price Target to $16.5

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surge above $104,000 has pushed the market into a <a href="https://www.benzinga.com/money/bitcoin-price-prediction">"high-risk, high-reward" zone</a>, with a structure that mirrors previous bull rallies, according to Glassnode's report on Tuesday.
What Happened: The <a href="https://www.papermark.com/view/cmal8lffh0001l404m7c1gm5l">report</a> suggests that while profit-taking incentives are rising sharply, the rally could sustain momentum if demand from new participants continues to grow.
"The market has now entered a high-risk, high-reward structure, with 94% of supply in profit, NUPL nearing euphoric levels, and the Realized Profit/Loss ratio elevated at 2.38," the report said.
"However, if demand continues to build in response to the rally – particularly among new entrants – this structure has the potential to persist for several more weeks, similar to prior bullish phases."
Glassnode&#8217;s assessment positions the current market as delicately balanced. 
On one side, elevated unrealized profits create strong incentives for investors to sell. 
On the other, multiple indicators, across spot, futures and options markets, suggest ongoing accumulation and confidence.
The rally has been distinctly spot-driven, with aggressive net taker buy pressure reflecting strong conviction from buyers. 
Spot cumulative volume delta (CVD) flipped from -$149 million to +$9.91 million, while spot trading volume recovered to $7.89 billion after weeks of low participation. 
These moves confirm that buyers are stepping in even at elevated price levels.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45380119/solana-faces-competition-from-sui-ton-base-blockchains-report">Solana Faces Competition From Sui, Ton, Base Blockchains: Report</a>
Derivatives markets are playing catch-up. 
Futures open interest rose from $33.3 billion to $34.1 billion, funding rates turned positive, and perpetual CVD jumped to +$504 million, indicating a build-up of long leverage. 
Options markets mirrored this bullish bias, with open interest reaching $29.5 billion and skew metrics showing a strong tilt toward call buying.
Institutional participation via spot ETFs has also remained strong. 
Net inflows dipped slightly from $1.36 billion to $1.25 billion but still sit well above long-term averages, according to the report. 
What&#8217;s Next: The report tempers its optimism with some caution.
Key on-chain fundamentals, like active addresses and fee volumes are improving but remain modest compared to prior bull runs. 
The share of "hot capital," or short-term speculative inflows, remains low at 29%, highlighting a hesitance from newer market participants to engage.
Bitcoin's price structure is bullish but precarious, supported by strong momentum but vulnerable if fresh demand fails to materialize. 
Glassnode&#8217;s analysts underline that the next phase of the rally will depend not just on metrics, but on market psychology: whether enough new buyers are willing to step in and absorb realized profits from early holders.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45372870/robinhood-to-acquire-canadas-wonderfi-for-178m-all-cash-deal">Robinhood To Acquire Canada&#8217;s WonderFi For $178M All-Cash Deal</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Rally Is In A 'High-Risk, High-Reward' Zone: Glassnode

Aemetis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTX#NASDAQ">AMTX</a>) on Tuesday announced a <a href="https://www.benzinga.com/pressreleases/25/05/g45372712/aemetis-biogas-signs-27-million-agreement-with-centuri-to-build-gas-cleanup-systems-for-15-dairy-d" target="_blank" rel="noreferrer noopener">$27 million equipment agreement</a> with Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>), marking a significant step forward in its renewable natural gas (RNG) infrastructure strategy.
The agreement, made through Aemetis' subsidiary, Aemetis Biogas, will support the deployment of biogas cleanup systems across 15 dairy digesters in California's Central Valley. These installations are part of a larger initiative to produce RNG from 50 dairies already under contract.
Aemetis underscored that its partnership with Centuri extends well beyond this initial equipment deal. According to Chairman and CEO Eric McAfee, Centuri will also provide construction management and pipeline assembly services for future energy efficiency and carbon reduction initiatives. McAfee pointed to Centuri's strong track record in executing large-scale industrial and pipeline infrastructure projects.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45379707/sp-500-to-6500-goldman-sachs-trims-recession-odds-as-trump-backs-off-on-tariffs" rel="noreferrer noopener">S&amp;P 500 To 6,500? Goldman Sachs Trims Recession Odds As Trump Backs Off On Tariffs</a>
In addition to the digester expansion, Aemetis is moving forward with several significant projects. These include scaling RNG production to exceed 1 million MMBtu annually and implementing a vapor recompression system at its Keyes ethanol facility, which is expected to boost annual cash flow by $32 million starting in 2026.
The company is also advancing a carbon sequestration initiative capable of storing 1.4 million tons of CO₂ per year and a 78 million-gallon-per-year sustainable aviation fuel and renewable diesel plant. Further industrial-scale developments are being negotiated at the company's Riverbank site.
Price Action: AMTX shares are trading higher by 7.39% to $1.525, and CTRI is up by 8.55% to $21.20 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom" target="_blank" rel="noreferrer noopener">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a></li>
</ul>
Image via Shutterstock

Contracts

AMTX

CTRI

Why Is Aemetis Stock Trading Higher On Tuesday?

<a href="https://www.bloomberg.com/news/articles/2025-05-13/goldman-in-talks-to-expand-its-marcus-retail-bank-into-ireland?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-13/goldman-in-talks-to-expand-its-marcus-retail-bank-into-ireland?embedded-checkout=true</a>

'Goldman in Talks to Expand Its Marcus Retail Bank Into Ireland'- Bloomberg

Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) has outperformed the market over the past 10 years by 4.16% on an annualized basis producing an average annual return of 14.83%. Currently, Wheaton Precious Metals has a market capitalization of $35.59 billion. 
Buying $100 In WPM: If an investor had bought $100 of WPM stock 10 years ago, it would be worth $385.07 today based on a price of $78.43 for WPM at the time of writing.
<h3>Wheaton Precious Metals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747153850_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Wheaton Precious Metals Stock In The Last 10 Years

UBS analyst Michael Goldsmith maintains Four Corners Property Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>) with a Buy and lowers the price target from $33 to $30.

FCPT

UBS Maintains Buy on Four Corners Property Tr, Lowers Price Target to $30

WIIM

Applovin shares are trading higher after the company last week reported better-than-expected Q1 financial results.

Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares are trading higher on Tuesday after the company disclosed that Saudi Arabia-based AviLease placed its first direct order for the purchase of 20 737-8 jets, along <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45379503/avilease-places-first-direct-boeing-order-for-up-to-30-737-max-jets" rel="noreferrer noopener">with options for an additional 10 aircraft.</a>
This agreement allows AviLease to expand its increasing fleet and offer its airline clients access to the newest, fuel-efficient aircraft models.
This single-aisle aircraft order supports the Kingdom of Saudi Arabia&#8217;s strategic vision to become a global center for aviation.
These airplanes is expected to contribute to the nation&#8217;s objective of accommodating 330 million passengers and attracting 150 million visitors each year by 2030.
Edward O&#8217;Byrne, CEO of AviLease added, &#8220;Building on our recently achieved investment grade ratings, this transaction proves our ability to transact across all market channels, including sale and lease-back, secondary trading, M&amp;A and now direct OEM purchasing.&nbsp;These new aircraft will accelerate our growth and enable us to deliver the industry&#8217;s latest generation, fuel–efficient fleet solutions.&#8221;
Last week, Boeing shares rose after Taiwan&#8217;s&nbsp;China Airlines&nbsp;ordered&nbsp;14 of the fuel-efficient 777X aircraft, becoming the first in Taiwan to do so. The airline plans to use them for <a href="https://www.benzinga.com/news/contracts/25/05/45290030/boeings-secures-order-from-taiwans-china-airlines" target="_blank" rel="noreferrer noopener">long-haul routes to North America and Europe</a>.
In the first quarter, the company booked 221 net orders and delivered 130 commercial airplanes, with a backlog of over 5,600 planes valued <a target="_blank" href="https://www.benzinga.com/25/04/44948499/boeing-stock-jumps-after-q1-2025-results-production-expansion-plans-for-737-and-787" rel="noreferrer noopener">at&nbsp;$460 billion</a>.
Moreover, the company&#8217;s shares got a boost from a landmark trade agreement between the U.S. and the U.K. signed last week, in which the U.K. pledged&nbsp;to purchase $10 billion worth of Boeing aircraft, fueling investor optimism about Boeing&#8217;s international order <a target="_blank" href="https://www.benzinga.com/general/travel/25/05/45299009/boeing-stock-rises-on-10-billion-uk-aircraft-deal-in-landmark-trade-pact" rel="noreferrer noopener">pipeline and overall revenue outlook.</a>
Investors can gain exposure to the stock via&nbsp;the iShares U.S. Aerospace &amp; Defense ETF (BATS:<a target="_blank" href="https://www.benzinga.com/stock/ITA#BATS" rel="noreferrer noopener"> ITA</a>) and&nbsp;Direxion Daily BA Bull 2X Shares&nbsp;(NASDAQ:<a target="_blank" href="https://www.benzinga.com/stock/BOEU#NASDAQ" rel="noreferrer noopener"> BOEU</a>).
Price Action: BA shares are trading higher by 3.07% at $204.63&nbsp;at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45368534/china-greenlights-boeing-jet-arrivals-again-as-90-day-tariff-pause-with-us-brings-relief" target="_blank" rel="noreferrer noopener">China Ends Freeze On Boeing Deliveries As 90-Day Tariff Pause With US Brings Relief: Report</a></li>
</ul>
Photo: JHVEPhoto via Shutterstock

Equities

Large Cap

Global

Boeing Welcomes New Saudi Arabian Partner: AviLease Orders 20 Fuel-Efficient Jets

Stifel analyst Simon Yarmak maintains Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) with a Buy and raises the price target from $168.5 to $180.

Stifel Maintains Buy on Simon Property Group, Raises Price Target to $180

UBS analyst Michael Goldsmith maintains Getty Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTY#NYSE">GTY</a>) with a Neutral and lowers the price target from $32 to $29.

UBS Maintains Neutral on Getty Realty, Lowers Price Target to $29

Stifel analyst Adam Borg maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Hold and lowers the price target from $38 to $29.

Stifel Maintains Hold on Rapid7, Lowers Price Target to $29

Stifel analyst Tore Svanberg maintains Power Integrations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWI#NASDAQ">POWI</a>) with a Buy and raises the price target from $70 to $75.

POWI

Stifel Maintains Buy on Power Integrations, Raises Price Target to $75

United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) shares are trading higher on Tuesday after the company revealed its new United Elevated interior for incoming Boeing 787-9 aircraft targeting the <a target="_blank" href="https://www.benzinga.com//node/45371239" rel="noreferrer noopener">international premium travel market</a>.
The highlights include two new, larger Polaris Studio suites (8 total) with privacy doors, a companion ottoman, premium amenities (including Ossetra caviar), wireless charging, Bluetooth, and a massive 27-inch 4K OLED screen (the largest among U.S. carriers).
Standard United Polaris seats are also being upgraded to suites with sliding doors and larger 19-inch 4K OLED screens.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45173637/jetzero-secures-235m-u-s-air-force-contract-as-united-airlines-eyes-200-orders-for-revolutionary-blended-wing-aircraft" rel="noreferrer noopener">JetZero Secures $235M U.S. Air Force Contract As United Airlines Eyes 200 Orders For Revolutionary Blended-Wing Aircraft</a>
All United Polaris business class passengers will continue to have access to the airline&#8217;s six award-winning United Polaris lounges.
The company anticipates receiving its first Boeing 787-9 with the Elevated interior before the close of 2025, with the inaugural international passenger flights scheduled for 2026 from San Francisco to Singapore and San Francisco to London.
The initial deliveries of 787-9 aircraft with the Elevated interior will have 8 Polaris Studio suites (1-2-1), 56 Polaris suites (1-2-1, window/center or aisle-facing options), 35 Premium Plus seats (2-3-2, most in fleet), and 123 Economy/Economy Plus seats (3-3-3).
This differs from the current 787-9s with 48 Polaris, 21 Premium Plus, 39 Economy Plus, and 149 Economy seats.
Notably, United has invested over $150 million in enhancing its food and beverage offerings this year.
&#8220;We already deliver a superior international experience and fly to the most places across the Atlantic and Pacific &#8211; these new innovations provide a more premium experience overall, give customers even more reasons to choose United, and set our airline up to grow into the next decade and beyond,&#8221; said&nbsp;Andrew Nocella, EVP and Chief Commercial Officer at United.
In April, the company reported&nbsp;first-quarter&nbsp;revenue of&nbsp;$13.21 billion, missing&nbsp;analyst estimates of&nbsp;$13.25 billion and adjusted EPS of 91 cents per share, <a target="_blank" href="https://www.benzinga.com//node/44826858" rel="noreferrer noopener">beating estimates of 76 cents per share</a>.
Price Action: UAL shares are up 3.02% to $81.00 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/travel/25/05/45341520/faa-mulls-cutting-flights-at-newark-airport-amid-staffing-woes-and-equipment-failures-report" target="_blank" rel="noreferrer noopener">FAA Mulls Cutting Flights At Newark Airport Amid Staffing Woes And Equipment Failures: Report</a></li>
</ul>
Photo by Miguel Lagoa via Shutterstock

United Airlines Bets On Luxury Travel, Unveils Ultra-Premium Polaris Studio Suites

UBS analyst Joshua Spector maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Buy and lowers the price target from $51 to $50.

MEOH

UBS Maintains Buy on Methanex, Lowers Price Target to $50

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and raises the price target from $8 to $12.5.

OPRX

Stifel Maintains Buy on OptimizeRx, Raises Price Target to $12.5

UBS analyst Michael Goldsmith maintains NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a Neutral and lowers the price target from $44 to $43.

Comments

Enovix

Enovix (ENVX) オプション

Loading...

ニュース

パートナーシップ

ベンジンガ・グローバル